Antibiotic Pipeline Overflows New drugs and new classes intrigue IDWeek audience

"We have new drugs for bad bugs," quipped co-moderator Cesar Arias, MD, PhD, of the University of Texas Medical School at Houston. The new drugs include beta-lactamase inhibitors, a cephalosporin, an aminoglycoside, a fluoroquinolone, and a tetracycline, as well as several first-in-class medications. Themes that emerged during the discussion were twofold: The new drugs in established classes aim to overcome some of the safety issues of their predecessors And the approach to resistance is much more nuanced than it has been in the past, so that doctors will soon be able to choose medications that target specific mechanisms of resistance Already available is delafloxacin (Baxdela), a new fluoroquinolone that won FDA approval in June for acute bacterial skin and skin structure infections (ABSSSI), according to Sue Cammarata https://www.medpagetoday.com/MeetingCoverage/IDWeek/68389?xid=nl_mpt_DHE_2017-10-07&eun=g721819d0r&pos=0